Goodwill and Intangible Assets, Net (Tables)

6 Months Ended

Jun. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Carrying Value of Goodwill

The carrying values of goodwill assigned to the Company’s operating segments are as follows:

	Cell Therapy			Biobanking		Degenerative Disease		Total
Balance at December 31, 2022	$	112,347		$	7,347	$	-	$	119,694
Impairment(1)		(29,633	)		-		-		(29,633	)
Balance at June 30, 2023	$	82,714		$	7,347	$	-	$	90,061

(1) As of June 30, 2023 and December 31, 2022, the accumulated goodwill impairment for the Degenerative Disease reporting unit was $3,610 and for Cell Therapy the accumulated goodwill impairment was $29,633 and $0 as of June 30, 2023 and December 31, 2022, respectively.

Schedule of Intangible Assets, Net

Intangible assets, net consisted of the following:

	June 30, 2023			December 31, 2022			Estimated Useful Lives
Amortizable intangible assets:
Developed technology	$	16,810		$	16,810		11-16 years
Customer relationships		2,413			2,413		10 years
Trade names & trademarks		570			570		10-13 years
Reacquired rights		4,200			4,200		6 years
		23,993			23,993
Less: Accumulated amortization
Developed technology		(7,131	)		(6,549	)
Customer relationships		(1,566	)		(1,435	)
Trade names & trademarks		(302	)		(275	)
Reacquired rights		(3,587	)		(3,240	)
		(12,586	)		(11,499	)
Amortizable intangible assets, net		11,407			12,494
Non-amortized intangible assets
Acquired IPR&D product rights		700			108,500		indefinite
	$	12,107		$	120,994